Patents Assigned to Prosensa B.V.
  • METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
    Publication number: 20140221458
    Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolate muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.
    Type: Application
    Filed: March 7, 2014
    Publication date: August 7, 2014
    Applicants: Prosensa Technologies B.V., Academisch Ziekenhuis Leiden, Prosensa Holding B.V., Prosensa B.V.
    Inventors: Josephus Johannes De Kimpe, Annemieke Aartsma-Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
    Publication number: 20140128592
    Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolate muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.
    Type: Application
    Filed: December 19, 2013
    Publication date: May 8, 2014
    Applicants: Prosensa Technologies B.V., Academisch Ziekenhuis Leiden, Prosensa Holding B.V., Prosensa B.V.
    Inventors: Josephus Johannes De Kimpe, Annemieke Aartsma-Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
    Publication number: 20140113955
    Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolate muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.
    Type: Application
    Filed: December 4, 2013
    Publication date: April 24, 2014
    Applicants: Prosensa Technologies B.V., Academisch Ziekenhuis Leiden, Prosensa Holding B.V., Prosensa B.V.
    Inventors: Josephus Johannes De Kimpe, Annemieke Aartsma-Rus, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen
  • Mannose-6-phosphate receptor mediated gene transfer into muscle cells
    Publication number: 20120122801
    Abstract: The invention relates to glycoside-compound conjugates for use in antisense strategies and/or gene therapy. The conjugates comprise a glycoside linked to a compound, in which the glycoside is a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell. For example the cells are muscle cells of a Duchenne Muscular Dystrophy (DMD) patient and the conjugate comprises an antisense oligonucleotide which causes ex on skipping and induces or restores the synthesis of dystrophin or variants thereof.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 17, 2012
    Applicant: Prosensa B.V.
    Inventor: Gerard Johannes PLATENBURG
  • METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
    Publication number: 20120022134
    Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in said method.
    Type: Application
    Filed: April 26, 2011
    Publication date: January 26, 2012
    Applicants: PROSENSA TECHNOLOGIES B.V., ACADEMISCH ZIEKENHUIS LEIDEN, PROSENSA HOLDING BV, PROSENSA B.V.
    Inventors: JOSEPHUS JOHANNES DE KIMPE, GERARDUS JOHANNES PLATENBURG, JUDITH CHRISTINA THEODORA VAN DEUTEKOM, ANNEMIEKE AARTSMA-RUS, GARRIT-JAN BOUDEWIJN VAN OMMEN
  • METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
    Publication number: 20110263682
    Abstract: The invention relates a method wherein a molecule is used for inducing and/or promoting skipping of at least one of exon 43, exon 46, exons 50-53 of the DMD pre-mRNA in a patient, preferably in an isolated cell of a patient, the method comprising providing said cell and/or said patient with a molecule. The invention also relates to said molecule as such.
    Type: Application
    Filed: April 26, 2011
    Publication date: October 27, 2011
    Applicants: Academisch Ziekenhuis Leiden, Prosensa Holding BV, Prosensa Technologies B.V., Prosensa B.V.
    Inventors: Josephus Johannes De Kimpe, Gerardus Johannes Platenburg, Judith Christina Theodora Van Deutekom, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
  • Mannose-6-phosphate receptor mediated gene transfer into muscle cells
    Publication number: 20110110960
    Abstract: The invention relates to glycoside-compound conjugates for use in antisense strategies and/or gene therapy. The conjugates comprise a glycoside linked to a compound, in which the glycoside is a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell. For example the cells are muscle cells of a Duchenne Muscular Dystrophy (DMD) patient and the conjugate comprises an antisense oligonucleotide which causes exon skipping and induces or restores the synthesis of dystrophin or variants thereof.
    Type: Application
    Filed: October 5, 2010
    Publication date: May 12, 2011
    Applicant: Prosensa B.V.
    Inventor: Gerard Johannes PLATENBURG
  • Novel mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy
    Publication number: 20110020430
    Abstract: Methods for treating neuroblastoma in a subject are provided. The methods include administering to the subject nucleic acid that is capable of causing a significant reduction of the amount of doublecortin like protein (DCL) in the subject. The nucleic acids include antisense oligonucleotides and small interfering RNA.
    Type: Application
    Filed: May 24, 2010
    Publication date: January 27, 2011
    Applicants: PROSENSA B.V., Universiteit Leiden
    Inventors: Erno VREUGDENHIL, Petra Van Kuik-Romeijn
  • mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy
    Patent number: 7754871
    Abstract: The present invention relates to novel nucleic acid and protein molecules and their use in neuroblastoma therapy and diagnosis.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: July 13, 2010
    Assignees: Prosensa B.V., Universiteit Leiden
    Inventors: Erno Vreugdenhil, Petra Van Kuik-Romeijn
  • Mannose-6-phosphate receptor mediated gene transfer into muscle cells
    Publication number: 20060148740
    Abstract: The invention relates to glycoside-compound conjugates for use in antisense strategies and/or gene therapy. The conjugates comprise a glycoside linked to a compound, in which the glycoside is a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell. For example the cells are muscle cells of a Duchenne Muscular Dystrophy (DMD) patient and the conjugate comprises an antisense oligonucleotide which causes exon skipping and induces or restores the synthesis of dystrophin or variants thereof.
    Type: Application
    Filed: January 5, 2005
    Publication date: July 6, 2006
    Applicant: Prosensa B.V.
    Inventor: Gerard Platenburg